Condition
HR-positive/HER2-negative Breast Cancer clinical trials and research
As of November 12, 2026, Find a Trial lists 2 HR-positive/HER2-negative Breast Cancer clinical trials that are recruiting, in China. By phase: Phase 2 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 1Country
All recruiting trials (2)
-
Neoadjuvant QL1706 (Iparomlimab + Tuvonralimab) with chemotherapy for HR-positive, HER2-negative breast cancer
This trial will test whether giving QL1706 (two immunotherapy antibodies) together with paclitaxel and carboplatin before surgery helps people with hormone receptor–positive, HER2‑negative breast cancer.
-
Combining radiotherapy and chemotherapy with Toripalimab for advanced breast cancer
This study is testing if combining radiotherapy and chemotherapy with a new drug called Toripalimab can help people with advanced breast cancer feel better and improve their treatment outcomes.
Related topics
Quick answers
How many HR-positive/HER2-negative Breast Cancer clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.